MOBILE VIEW  | 

SYMPTOMATIC DRUG PARENTERAL EXPOSURE

Classification   |    Detailed evidence-based information

Therapeutic Toxic Class

    A) This management is intended for use in the absence of a specific treatment protocol for a particular drug. It should be used when general guidelines may be needed for patient care. It may also be helpful when an experimental agent has been injected and there are no toxicity data available.

Specific Substances

    A) GENERAL TERMS
    1) DRUG PARENTERAL EXPOSURE, SYMPTOMATIC
    2) PARENTERAL EXPOSURE, SYMPTOMATIC
    3) SYMPTOMATIC PARENTERAL EXPOSURE
    4) PARENTERAL DRUG EXPOSURE

Life Support

    A) This overview assumes that basic life support measures have been instituted.

Clinical Effects

    0.2.1) SUMMARY OF EXPOSURE
    A) SUMMARY - Treat the patient, not the poison. Symptomatic and supportive care is the mainstay of therapy.
    B) The general approach to the poisoned patient is to:
    1) First assess the patient. Support vital functions as needed, monitor cardiac status, vital signs, fluid intake and output, body temperature, and mental status.
    2) Patients with coma or altered mental status should receive oxygen, naloxone (Narcan(R)), thiamine (in adults), and have glucose level measured immediately or receive D50.
    3) Assess the substance in question and the route of administration for potential toxicity.
    4) Appropriate laboratory tests should be ordered.
    C) Symptoms seen due to unknown poisons may occur to any of the body systems, and a thorough diagnostic evaluation should be performed on any patient involved in exposure to an unknown agent.
    0.2.5) CARDIOVASCULAR
    A) Dysrhythmias and hypotension may occur.
    0.2.6) RESPIRATORY
    A) Irritating substances may induce pulmonary edema or pneumonitis. Embolization of insoluble material may occur.

Laboratory Monitoring

    A) Appropriate laboratory evaluation is determined in part by the clinical condition of the patient. Initial history is often inaccurate and most deliberate parenteral exposures in adults and adolescents involve more than one drug.
    1) Serum electrolytes to evaluate for metabolic acidosis and a four hour acetaminophen level should be obtained if there is any possibility of mixed overdose or uncertain history.
    2) Tests of hepatic and renal function, arterial blood gases, pulse oximetry, and chest radiographs should be performed if clinically indicated.
    3) A 12-lead electrocardiogram should be performed to evaluate for dysrrhythmia, tachycardia, or interval prolongation.
    4) Pregnancy testing should be considered in women of childbearing potential as pregnancy may precipitate suicidal gestures and overdose may complicate the pregnancy.
    B) Toxicology screens and drug levels should be performed as indicated by history and clinical signs and symptoms.
    1) A variety of tests are available. General toxicology screens rarely provide information that alters the management of the asymptomatic, stable patient (an exception to this is an acetaminophen level).
    2) Blood, urine and syringe contents are potential analytical samples and should be saved.
    3) Consult the clinical toxicology laboratory early so that the correct specimens are obtained for the suspected poison.

Treatment Overview

    0.4.2) ORAL/PARENTERAL EXPOSURE
    A) Please refer to parenteral section for treatment information.
    0.4.6) PARENTERAL EXPOSURE
    A) This management is intended for use in the absence of a specific treatment protocol for a particular drug when some guidelines may be needed for patient care. It may also be helpful when an experimental agent has been injected and there are no data available on its toxicity.
    B) Up to 50% of all initial histories are incorrect; history should be obtained from several individuals if possible. Important information to be obtained from products includes the type of packaging, the amount in the package, and the amount remaining after either injection or ingestion, or both. In suspected mixed ingestions, having a family member bring in all medications available in the home may be useful.
    C) The goal is to remove, detoxify, or prevent absorption of substances administered parenterally.
    D) GENERAL TREATMENT
    1) Assess life threatening potential.
    2) Establish respiration and create an artificial airway, if needed.
    3) HYPOTENSION
    a) HYPOTENSION: Infuse 10 to 20 mL/kg isotonic fluid. If hypotension persists, administer dopamine (5 to 20 mcg/kg/min) or norepinephrine (ADULT: begin infusion at 0.5 to 1 mcg/min; CHILD: begin infusion at 0.1 mcg/kg/min); titrate to desired response.
    b) Pulmonary artery catheterization should be considered in patients with persistent hypotension to optimize utilization of fluids and vasopressors.
    4) VENTRICULAR DYSRHYTHMIAS
    a) VENTRICULAR DYSRHYTHMIAS/SUMMARY: Institute continuous cardiac monitoring, obtain an ECG, and administer oxygen. Evaluate for hypoxia, acidosis, and electrolyte disorders. Lidocaine and amiodarone are generally first line agents for stable monomorphic ventricular tachycardia, particularly in patients with underlying impaired cardiac function. Amiodarone should be used with caution if a substance that prolongs the QT interval and/or causes torsades de pointes is involved in the overdose. Unstable rhythms require immediate cardioversion.
    5) Aggressively treat and evaluate coma regardless of suspected cause. Intubate and ventilate as needed. Comatose patients should receive oxygen, naloxone (Narcan(R)), thiamine (adults) and either D50 or rapid determination of glucose level. Check core temperature to evaluate for hypo- or hyperthermia. Consider evaluation for CNS lesion or infection with CT and lumbar puncture.
    6) Perform serial examinations to determine whether the patient is improving or deteriorating.
    7) INTERFERENCE WITH BLOOD GLUCOSE MEASUREMENT: Patients receiving parenteral medications that contain maltose or galactose, or oral medications containing xylose, may have falsely elevated blood glucose levels measured using glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) based glucose monitoring systems. Some of these patients have been treated with insulin and developed life-threatening or fatal hypoglycemia. In addition, patients with true hypoglycemia may go untreated if the hypoglycemic state is masked by false elevation of glucose readings.

Range Of Toxicity

    A) In many cases the amount of toxin injected will be unknown, or the milligram/kilogram toxicity of the agent itself will be uncertain. It is the patient, not the poison, which should be treated in these cases, and until the toxic substance or the substance's toxicity has been more accurately determined the amount injected will have less relevance than the patient's clinical condition.

Summary Of Exposure

    A) SUMMARY - Treat the patient, not the poison. Symptomatic and supportive care is the mainstay of therapy.
    B) The general approach to the poisoned patient is to:
    1) First assess the patient. Support vital functions as needed, monitor cardiac status, vital signs, fluid intake and output, body temperature, and mental status.
    2) Patients with coma or altered mental status should receive oxygen, naloxone (Narcan(R)), thiamine (in adults), and have glucose level measured immediately or receive D50.
    3) Assess the substance in question and the route of administration for potential toxicity.
    4) Appropriate laboratory tests should be ordered.
    C) Symptoms seen due to unknown poisons may occur to any of the body systems, and a thorough diagnostic evaluation should be performed on any patient involved in exposure to an unknown agent.

Cardiovascular

    3.5.1) SUMMARY
    A) Dysrhythmias and hypotension may occur.
    3.5.2) CLINICAL EFFECTS
    A) CONDUCTION DISORDER OF THE HEART
    1) Atrial fibrillation with a rapid ventricular response has occurred following IV injection of gasoline (Greenberg et al, 1993).
    2) Bradycardia may develop after rapid intravenous administration of medications containing propylene glycol (Louis et al, 1967).
    B) HYPOTENSIVE EPISODE
    1) Hypotension may develop after rapid intravenous administration of medications containing propylene glycol (Louis et al, 1967).
    2) Hypotension developed in a 30 year old man after intravenous xylene injection (Sevcik et al, 1992).
    C) THROMBOPHLEBITIS
    1) Thrombophlebitis may develop at the injection site, particularly with irritating substances.
    D) PERIPHERAL ISCHEMIA
    1) Tissue ischemia may develop after inadvertent intraarterial injection.
    E) INJECTION SITE REACTION
    1) Sclerosis of the peripheral veins may occur following repeated injections of contaminated sympathomimetic substances. Two preferred access sites of drug abusers are the femoral vessels ("groin hit") and the great vessels of the neck ("pocket shot") (McCarroll & roszler, 1991).

Respiratory

    3.6.1) SUMMARY
    A) Irritating substances may induce pulmonary edema or pneumonitis. Embolization of insoluble material may occur.
    3.6.2) CLINICAL EFFECTS
    A) PULMONARY HEMORRHAGE
    1) CASE REPORT - A patient self-injecting 3 mL of charcoal lighter fluid (naphtha) IV developed a severe hemorrhagic pneumonitis (Vaziri et al, 1980).
    B) DISORDER OF RESPIRATORY SYSTEM
    1) CASE REPORT - Crepitus with a normal chest x-ray was reported after injection of lighter fuel intravenously in another case (Bushe, 1986).
    C) ACUTE LUNG INJURY
    1) CASE REPORT - A 30 year old man developed rapid onset of severe acute lung injury (pulmonary edema) after intravenous injection of xylene (Sevcik et al, 1992).
    D) THROMBOEMBOLUS
    1) Embolization of insoluble particles may occur. This complication is most common in the setting of chronic injection of illicit drugs (McCarroll & roszler, 1991) Kulaylat et al, 1993).
    E) PNEUMOTHORAX
    1) "POCKET SHOT" - In patients using illicit IV drugs, such as cocaine, pocket refers to the general area of the supraclavicular fossa. Addicts gain access to the jugular, subclavian, and brachiocephalic veins through the pocket. Pneumothorax is a common complication of the pocket shot. Since the lung apex is in direct proximity to the vascular structures in the pocket, pneumothorax may result when the needle deviates from its desired course (subclavian injection) (McCarroll & roszler, 1991).
    F) PULMONARY EMBOLISM
    1) Illicit intravenous injections, especially chronic repeated ones, have resulted in septic pulmonary emboli. Necrotizing pneumonia may also occur in these patients, probably due to septic embolism or septic infarction if focal (McCarroll & roszler, 1991).

Dermatologic

    3.14.2) CLINICAL EFFECTS
    A) INJECTION SITE REACTION
    1) Local tissue injury and necrosis may develop with extravasation of injected material (Heckler, 1989) Lipson & Yannuzzi, 1989).
    2) "SKIN POP" - Illicit subcutaneous ("skin pop") drug injection injuries may result in abscess formation at the injection site as well as injection site cellulitis, lymphangitis, or lymphadenopathy. Local ischemia induced by vasoconstriction from these agents may occur. Other effects of illicit subcutaneous injections may include suppurative tenosynovitis, joint space infections, osteomyelitis, gangrene, and bacteremia (Thomas et al, 1995).

Musculoskeletal

    3.15.2) CLINICAL EFFECTS
    A) NECROSIS
    1) CASE REPORT - Deep intramuscular injection of lamp oil into the pronator teres muscle of the upper left arm by a 21-year-old male attempting suicide produced severe muscle necrosis requiring debridement. No evidence of pulmonary sequelae was found (Kresel et al, 1987).
    B) COMPARTMENT SYNDROME
    1) A 17-year-old woman developed compartment syndrome of both hands with necrosis of fat and interosseus muscles bilaterally after injecting the dorsum of both hands with an insecticide containing kerosene and aromatic hydrocarbons (Larsen et al, 1992).
    C) INJECTION SITE ABSCESS
    1) Subcutaneously administered hydrocarbons produce sterile abscess formation and cellulitis at the site of injection. These effects may be delayed and progress extensively (Wedin & Jones, 1984; Wason & Greiner, 1986).

Endocrine

    3.16.2) CLINICAL EFFECTS
    A) HYPOGLYCEMIA
    1) WITH POISONING/EXPOSURE
    a) INTERFERENCE WITH BLOOD GLUCOSE MEASUREMENT - Patients receiving parenteral medications that contain maltose or galactose, or oral medications containing xylose, may have falsely elevated blood glucose levels measured using glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) based glucose monitoring systems. Some of these patients have been treated with insulin, and developed life-threatening or fatal hypoglycemia (Anon, 2005).

Immunologic

    3.19.2) CLINICAL EFFECTS
    A) ANAPHYLACTOID REACTION
    1) Anaphylaxis is more likely to occur after parenteral administration of a drug than after oral administration.(Flomenbaum & Lewin, 1994).

Monitoring Parameters Levels

    4.1.1) SUMMARY
    A) Appropriate laboratory evaluation is determined in part by the clinical condition of the patient. Initial history is often inaccurate and most deliberate parenteral exposures in adults and adolescents involve more than one drug.
    1) Serum electrolytes to evaluate for metabolic acidosis and a four hour acetaminophen level should be obtained if there is any possibility of mixed overdose or uncertain history.
    2) Tests of hepatic and renal function, arterial blood gases, pulse oximetry, and chest radiographs should be performed if clinically indicated.
    3) A 12-lead electrocardiogram should be performed to evaluate for dysrrhythmia, tachycardia, or interval prolongation.
    4) Pregnancy testing should be considered in women of childbearing potential as pregnancy may precipitate suicidal gestures and overdose may complicate the pregnancy.
    B) Toxicology screens and drug levels should be performed as indicated by history and clinical signs and symptoms.
    1) A variety of tests are available. General toxicology screens rarely provide information that alters the management of the asymptomatic, stable patient (an exception to this is an acetaminophen level).
    2) Blood, urine and syringe contents are potential analytical samples and should be saved.
    3) Consult the clinical toxicology laboratory early so that the correct specimens are obtained for the suspected poison.
    4.1.2) SERUM/BLOOD
    A) BLOOD/SERUM CHEMISTRY
    1) Appropriate laboratory evaluation is determined in part by the clinical condition of the patient. Initial history is often inaccurate and many deliberate parenteral exposures in adults and adolescents involve more than one substance or drug or contaminant.
    2) Serum electrolytes to evaluate for metabolic acidosis and a four-hour acetaminophen level should be obtained if there is any possibility of mixed overdose, oral and parenteral exposures, or uncertain history.
    3) Tests of hepatic and renal function should be performed if clinically indicated.
    4) Pregnancy testing should be considered in women of childbearing potential, as the exposure may complicate the pregnancy.
    B) ACID/BASE
    1) Obtain arterial blood gases, pulse oximetry, and chest radiographs if clinically indicated.
    C) INTERFERENCE WITH BLOOD GLUCOSE MEASUREMENT -
    1) Patients receiving parenteral medications that contain maltose or galactose, or oral medications containing xylose, may have falsely elevated blood glucose levels measured using glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) based glucose monitoring systems. Some of these patients have been treated with insulin, and developed life-threatening or fatal hypoglycemia. In addition, patients with true hypoglycemia may go untreated if the hypoglycemic state is masked by false elevation of glucose readings (Anon, 2005). The following products may interfere with GDH-PQQ based glucose monitoring systems:
    Trade nameProper NameManufacturerSugarSugar concentration
    Octagam 5% Immune Globulin Intravenous (Human)OctapharmaMaltose10%
    Gamimune N 5%Immune Globulin Intravenous (Human) 5% Solvent/Detergent TreatedTalecrisMaltose9% to 11%
    Win Rho SDF Liquid*Rho(D) Immune Globulin Intravenous (Human)CangeneMaltose10%
    Vaccinia Immune Globulin (Human)Vaccinia Immune Globulin (Human)CangeneMaltose10%
    D-Xylose USPd-XyloseNERL Diagnostics, othersd-XyloseUsual dose 25 g
    Extraneal(Icodextrin) Peritoneal Dialysis SolutionBaxterIcodextrin7.5 g/100 mL

    a) * = No Interference with glucose testing when administered at the recommended dose.
    4.1.3) URINE
    A) URINARY LEVELS
    1) 50 to 100 mL of urine should be collected and sent to the laboratory. Hourly or timed urine specimens may be useful in certain exposures such as heavy metals - discuss with laboratory. Specific levels, half life, etc are found in specific managements.
    4.1.4) OTHER
    A) OTHER
    1) ECG
    a) A 12-lead electrocardiogram should be performed to evaluate for dysrrhythmia, tachycardia, or interval prolongation.

Radiographic Studies

    A) CHEST RADIOGRAPH
    1) Obtain a chest radiograph in patients with significant pulmonary symptoms or hemodynamic instability.
    B) RADIOGRAPHIC-OTHER
    1) Radiographs of the chest, abdomen and soft tissues may be helpful in localizing injected radiopaque materials (eg heavy metals).

Methods

    A) MULTIPLE ANALYTICAL METHODS
    1) Toxicology screens and drug levels should be performed as indicated by history and clinical signs and symptoms. A variety of tests are available. General toxicology screens rarely provide information that alters the management of the asymptomatic, stable patient (an exception to this is an acetaminophen level). Blood, urine and syringe contents are potential analytical samples and should be saved. Consult the clinical toxicology laboratory early so that the correct specimens are obtained for the suspected poison.

Life Support

    A) Support respiratory and cardiovascular function.

Monitoring

    A) Appropriate laboratory evaluation is determined in part by the clinical condition of the patient. Initial history is often inaccurate and most deliberate parenteral exposures in adults and adolescents involve more than one drug.
    1) Serum electrolytes to evaluate for metabolic acidosis and a four hour acetaminophen level should be obtained if there is any possibility of mixed overdose or uncertain history.
    2) Tests of hepatic and renal function, arterial blood gases, pulse oximetry, and chest radiographs should be performed if clinically indicated.
    3) A 12-lead electrocardiogram should be performed to evaluate for dysrrhythmia, tachycardia, or interval prolongation.
    4) Pregnancy testing should be considered in women of childbearing potential as pregnancy may precipitate suicidal gestures and overdose may complicate the pregnancy.
    B) Toxicology screens and drug levels should be performed as indicated by history and clinical signs and symptoms.
    1) A variety of tests are available. General toxicology screens rarely provide information that alters the management of the asymptomatic, stable patient (an exception to this is an acetaminophen level).
    2) Blood, urine and syringe contents are potential analytical samples and should be saved.
    3) Consult the clinical toxicology laboratory early so that the correct specimens are obtained for the suspected poison.

Oral Exposure

    6.5.3) TREATMENT
    A) GENERAL TREATMENT
    1) See the PARENTERAL EXPOSURE treatment section for further information.

Enhanced Elimination

    A) SUMMARY
    1) Appropriate use of techniques to enhance elimination of toxins depends on specific knowledge of chemical properties (pKa, molecular size), active forms, kinetics (volume of distribution, metabolism and route of elimination), and protein binding. All of these techniques have inherent risks and should not be utilized unless specifically indicated.
    B) DIURESIS
    1) FORCED DIURESIS: May be useful in serious poisonings if the drug is excreted in the urine in active form. The technique should not be used unless it is specifically indicated, as it may increase the problem of pulmonary or cerebral edema, common complications in the poisoned patient.
    a) Hypertonic or pharmacologic diuretics should be given along with adequate fluids. Usual urine flow is 0.5 to 2 milliliters/kilogram/hour and with forced diuresis should be 3 to 6 milliliters/kilogram/hour.
    b) Forced diuresis may enhance the excretion of lithium, bromides, and other drugs excreted primarily by the kidneys.
    2) URINARY ALKALINIZATION/EFFICACY
    a) ALKALINE DIURESIS: is effective in enhancing the elimination of drugs in which (1) significant amounts of the drug are excreted in the urine, and (2) the drug's Pka is such that urinary alkalinization will trap ionized drug in the tubular lumen and prevent reabsorption.
    1) ALKALINE FORCED DIURESIS: May enhance the excretion of acidic agents: barbiturates, isoniazid, and salicylates.
    3) SODIUM BICARBONATE/INITIAL DOSE
    a) Administer 1 to 2 milliequivalents/kilogram of sodium bicarbonate as an intravenous bolus. Add 132 milliequivalents (3 ampules) sodium bicarbonate and 20 to 40 milliequivalents potassium chloride (as needed) to one liter of dextrose 5 percent in water and infuse at approximately 1.5 times the maintenance fluid rate. In patients with underlying dehydration additional administration of 0.9% saline may be needed to maintain adequate urine output (1 to 2 milliliters/kilogram/hour). Manipulate bicarbonate infusion to maintain a urine pH of at least 7.5.
    4) SODIUM BICARBONATE/REPEAT DOSES
    a) Additional sodium bicarbonate (1 to 2 milliequivalents per kilogram) and potassium chloride (20 to 40 milliequivalents per liter) may be needed to achieve an alkaline urine.
    5) CAUTION
    a) Obtain hourly intake/output and urine pH. Assure adequate hydration and renal function prior to alkalinization. Do not administer potassium to an oliguric or anuric patient. Monitor fluid and electrolyte balance carefully. Monitor blood pH, especially in intubated patients, to avoid severe alkalemia.
    6) Osmotic load is also important and either type of diuretic should be given at intervals. Proximal reabsorption may occur if adequate osmotic load is not maintained in the tubule.
    7) CAUTION: Assure adequate hydration and renal function prior to alkalinization. Never give potassium to an oliguric patient. Follow serum calcium, phosphorus and magnesium during alkalinization.
    8) ACID FORCED DIURESIS: NO longer recommended for ANY agent including amphetamines, strychnine, and phencyclidine.
    C) DIALYSIS
    1) May be considered in those patients not responding to standard therapeutic measures to treat a dialyzable toxicant. It also may be considered a part of supportive care whether the toxicant is or is not dialyzable to treat the following: Stage 3 or 4 coma or hyperactivity caused by a dialyzable agent which cannot be treated by conservative means, marked hyperosmolality which is not due to easily corrected fluid problems, severe acid base disturbance not responding to therapy, or severe electrolyte disturbance not responding to therapy. Most effective in intoxication from chemicals with a volume of distribution of less than 1 liter/kilogram, which have low endogenous clearance, are not highly protein bound, are water soluble and have a molecular mass less than 500 (Pond, 1991).
    2) DEFINITE INDICATIONS: Dialysis should be initiated, regardless of clinical condition, in the following situations - following heavy metal chelation in patients with renal failure, following significant ethylene glycol or methanol ingestion.
    3) PROBABLE INDICATIONS: Dialysis is indicated in patients with severe intoxications with the following agents. The need for dialysis is based more on the patient's clinical condition than on specific drug levels. See specific drug managements for more detailed information.
    1) lithium
    2) phenobarbital
    3) salicylate
    4) theophylline
    4) POSSIBLE INDICATIONS: Dialysis MAY be initiated following exposure to the following agents, if clinical condition deems the procedure necessary (patient deteriorating despite intense supportive care):
    1) alcohols
    2) amphetamines
    3) anilines
    4) antibiotics
    5) boric acid
    6) barbiturates
    7) bromides
    8) calcium
    9) chlorates
    10) chloral hydrate
    11) ethanol
    12) iodides
    13) isopropanol
    14) isoniazid
    15) meprobamate
    16) paraldehyde
    17) fluorides
    18) potassium
    19) quinidine
    20) quinine
    21) strychnine
    22) thiocyanates
    5) RARE INDICATIONS: There is NO indication for dialysis, other than as a supportive measure in the presence of renal failure, following exposure to
    1) acetaminophen
    2) antidepressants
    3) antihistamines
    4) belladonna compounds
    5) benzodiazepines
    6) digitalis and related agents
    7) glutethimide
    8) hallucinogens
    9) heroin and other opioids
    10) methaqualone
    11) phenothiazines
    12) synthetic anticholinergics
    D) EXTRACORPOREAL ELIMINATION
    1) PERITONEAL DIALYSIS/EXCHANGE TRANSFUSION - May be more useful in small children than hemodialysis. The main point of these procedures may not be for removal of poison but restoration of fluid or acid-base balance. The infant who has been poisoned and whose serum sodium is rising because of excessive bicarbonate may be helped considerably by an exchange even if little poison is removed.
    E) HEMOPERFUSION
    1) Hemoperfusion may be more effective than dialysis in removing substances with larger molecular weights, poor water solubility or significant protein binding. Toxicants most effectively cleared by hemoperfusion have a volume of distribution less than 1 Liter/kilogram, are adsorbed by activated charcoal and have a low endogenous clearance (Pond, 1991). Complications include thrombocytopenia, air embolism, reduced glucose, calcium and urate levels, and hemorrhage secondary to the loss of clotting factor and the need for heparinization. Hemoperfusion may be more difficult to initiate and less effective from a practical standpoint than hemodialysis because it is less frequently performed in most institutions.
    2) It may be more effective than hemodialysis in clearing the following drugs:
    1) chloramphenicol
    2) diphenylhydantoin
    3) ethchlorvynol
    4) glutethimide
    5) phenobarbital
    6) pentobarbital
    7) theophylline
    F) HEMOFILTRATION
    1) Hemofiltration has the advantage of being able to remove compounds of larger molecular mass, up to 40,000, including metal chelate complexes. It is most effective for substances with a volume of distribution less than 1 Liter/kilogram and low endogenous clearance (Pond, 1991).

Summary

    A) In many cases the amount of toxin injected will be unknown, or the milligram/kilogram toxicity of the agent itself will be uncertain. It is the patient, not the poison, which should be treated in these cases, and until the toxic substance or the substance's toxicity has been more accurately determined the amount injected will have less relevance than the patient's clinical condition.

General Bibliography

    1) Anon: Important Safety Information on Interference With Blood Glucose Measurement Following Use of Parenteral Maltose/Parenteral Galactose/Oral Xylose-Containing Products. US Food and Drug Administration Center For Biologics Evaluation and Research. Rockville, MD. 2005. Available from URL: http://www.fda.gov/cber/safety/maltose110405.htm.
    2) Bouhouch R, El Houari T, Fellat I, et al: Pharmacological therapy in children with nodal reentry tachycardia: when, how and how long to treat the affected patients. Curr Pharm Des 2008; 14(8):766-769.
    3) Bushe CJ: Attempted suicide byb intravenous injection of lighter fuel presenting as an unusual cause of crepitus. Human Toxicol 1986; 5:347.
    4) Campbell IW & Ratcliffe JG: Suicidal insulin overdose managed by excision of insulin injection site. Br Med J 1982; 285:408-409.
    5) Casey PB, Dexter EM, & Michell J: The prospective value of the IPCS/EC/EAPCCT poisoning severity score in cases of poisoning. Clin Toxicol 1998; 36:215-217.
    6) Flomenbaum NE & Lewin NA: Goldfank's Toxicologic Emergencies, 5th ed, Appleton and Lange, East Norwalk, CT, 1994, pp 653-662.
    7) Goldfrank L, Flomenbaum NE, & Weismann RS: Goldfank's Toxicologic Emergencies, 5th ed, Appleton and Lange, East Norwalk, CT, 1994, pp 143-150.
    8) Greenberg MD, Robinson T, & Birrer R: Atrial fibrillation after intravenous administration of gasoline. Am Heart J 1993; 125:1438-1439.
    9) Heckler FR: Current thoughts on extravasation injuries. Clin Plast Surg 1989; 16(3):557-563.
    10) Kleinman ME, Chameides L, Schexnayder SM, et al: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Part 14: pediatric advanced life support. Circulation 2010; 122(18 Suppl.3):S876-S908.
    11) Kresel JJ, Courtemanche LA, & Evans FC: Distillate hydrocarbon exposure by the intrammuscular route (abstract). Vet Human toxicol 1987; 29:459-460.
    12) Larsen JM, Bindiger A, & Sherman R: Insecticide injection injuries to both hands: a case report. J Hand Surg 1992; 17A:1073-1075.
    13) Levine DF & Bulstrode C: Managing suicidal insulin overdose. Br Med J 1982; 285:974-975.
    14) Link MS, Berkow LC, Kudenchuk PJ, et al: Part 7: Adult Advanced Cardiovascular Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132(18 Suppl 2):S444-S464.
    15) Luedtke SA, Kuhn RJ, & McCaffrey FM: Pharmacologic management of supraventricular tachycardias in children. Part 2: Atrial flutter, atrial fibrillation, and junctional and atrial ectopic tachycardia. Ann Pharmacother 1997; 31(11):1347-1359.
    16) Mandapati R , Byrum CJ , Kavey RE , et al: Procainamide for rate control of postsurgical junctional tachycardia. Pediatr Cardiol 2000; 21(2):123-128.
    17) McCarroll KA & roszler MH: Lung disorders due to drug abuse. J Thoracic Imaging 1991; 6:30-35.
    18) McIntyre AS, Woolf VJ, & Burnham WR: Local excision of subcutaneous fat in the management of insulin overdose. Br J Surg 1986; 73:538.
    19) Netscher DT, Friedland JA, & Guzewicz RM: Mercury poisoning from intravenous injection: treatment by granuloma resection. Ann Plast Surg 1991; 26:592-596.
    20) Neumar RW , Otto CW , Link MS , et al: Part 8: adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(18 Suppl 3):S729-S767.
    21) Nicholson DP: The immediate management of overdose. Med Clin N Am 1983; 67:1279-1293.
    22) Peberdy MA , Callaway CW , Neumar RW , et al: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care science. Part 9: post–cardiac arrest care. Circulation 2010; 122(18 Suppl 3):S768-S786.
    23) Persson HE, Sjoberg GK, & Haines JA: Poisoning severity score. Grading of acute poisoning. Clin Toxicol 1998; 36:205-213.
    24) Pond SM: Extracorporeal techniques in the treatment of poisoned patients. Med J Australia 1991; 154:617-622.
    25) Product Information: Lidocaine HCl intravenous injection solution, lidocaine HCl intravenous injection solution. Hospira (per manufacturer), Lake Forest, IL, 2006.
    26) Product Information: dopamine hcl, 5% dextrose IV injection, dopamine hcl, 5% dextrose IV injection. Hospira,Inc, Lake Forest, IL, 2004.
    27) Product Information: norepinephrine bitartrate injection, norepinephrine bitartrate injection. Sicor Pharmaceuticals,Inc, Irvine, CA, 2005.
    28) Product Information: procainamide HCl IV, IM injection solution, procainamide HCl IV, IM injection solution. Hospira, Inc (per DailyMed), Lake Forest, IL, 2011.
    29) Ratnasamy C, Rossique-Gonzalez M, & Young ML: Pharmacological therapy in children with atrioventricular reentry: which drug?. Curr Pharm Des 2008; 14(8):753-761.
    30) Roden R & Fraser-Moodie A: Self-injection with mercury. Injury: the British Journal of Accident Surgery 1993; 24:191-192.
    31) Sauter D & Goldfrank L: Subcutaneous injection of metallic mercury: a can report. Vet Hum Toxicol 1986; 28:491.
    32) Sevcik P, Hep A, & Peslova: Intravenous xylene poisoning. Int Care MEd 1992; 18:377-378.
    33) Thomas WO, Almand JD, & Stark GB: Hand injuries secondary to subcutaneous illicit drug injections. Ann Plast Surg 1995; 34:27-31.
    34) Vanden Hoek TL, Morrison LJ, Shuster M, et al: Part 12: cardiac arrest in special situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122(18 Suppl 3):S829-S861.
    35) Vanden Hoek,TL; Morrison LJ; Shuster M; et al: Part 12: Cardiac Arrest in Special Situations 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. American Heart Association. Dallas, TX. 2010. Available from URL: http://circ.ahajournals.org/cgi/reprint/122/18_suppl_3/S829. As accessed 2010-10-21.
    36) Vaziri ND, Smith PJ, & Wilson A: Toxicity with intravenous injection of naphtha in man. Clin Toxicol 1980; 16:335-343.
    37) Walsh EP , Saul JP , Sholler GF , et al: Evaluation of a staged treatment protocol for rapid automatic junctional tachycardia after operation for congenital heart disease. J Am Coll Cardiol 1997; 29(5):1046-1053.
    38) Wason S & Greiner TP: Intravenous hydrocarbon abuse. Am J Emer Med 1986; 4:543-544.
    39) Wedin GP & Jones R: Parenteral administration of hydrocarbons. Clin Toxicol 1984; 22:485-492.
    40) de Caen AR, Berg MD, Chameides L, et al: Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132(18 Suppl 2):S526-S542.